Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

• Published in: International journal of geriatric psychiatry 2022-10, Vol.37 (10), p.n/a
• Main Authors: Nirogi, Ramakrishna, Jayarajan, Pradeep, Benade, Vijay, Shinde, Anil, Goyal, Vinod Kumar, Jetta, Satish, Ravula, Jyothsna, Abraham, Renny, Grandhi, Venkata Ramalingayya, Subramanian, Ramkumar, Pandey, Santosh Kumar, Badange, Rajesh Kumar, Mohammed, Abdul Rasheed, Jasti, Venkat, Ballard, Clive, Cummings, Jeffrey
• Format: Article
• Language: English
• Subjects: 5‐HT6 receptor; Aggression; Agitation; agitation/aggression; Alzheimer Disease - psychology; Alzheimer's disease; clinical trials; Cognition; Double-Blind Method; Geriatric psychiatry; Humans; Indoles; masupirdine; Neurodegenerative diseases; NPI‐12; Patients; Piperazines; Placebos; Psychomotor Agitation - drug therapy; Psychomotor Agitation - etiology; Psychomotor Agitation - psychology; Psychosis; Psychotic Disorders - drug therapy; Psychotic Disorders - psychology; Statistical analysis; Treatment Outcome
• ISSN: 0885-6230; 1099-1166; 1099-1166
• DOI: 10.1002/gps.5813

Objectives The effects of masupirdine on the neuropsychiatric symptoms were explored. Methods Masupirdine (SUVN‐502) was evaluated for its effects on cognition in patients with moderate AD. The prespecified primary outcome showed no drug‐placebo difference. Post hoc analyses of domains of the 12‐item neuropsychiatric inventory scale were carried out. Results In a subgroup of patients (placebo, n = 57; masupirdine 50 mg, n = 53; masupirdine 100 mg, n = 48) with baseline agitation/aggression symptoms ≥1, a statistically significant reduction in agitation/aggression scores was observed in masupirdine 50 mg (95% confidence interval (CI), −1.9 to −0.5, p